vs
Amplitude, Inc.（AMPL）与Vericel Corp（VCEL）财务数据对比。点击上方公司名可切换其他公司
Vericel Corp的季度营收约是Amplitude, Inc.的1.0倍（$92.9M vs $91.4M），Vericel Corp净利率更高（25.0% vs -19.3%，领先44.3%），Vericel Corp同比增速更快（23.3% vs 17.0%），Vericel Corp自由现金流更多（$12.8M vs $12.7M），过去两年Vericel Corp的营收复合增速更高（34.6% vs 12.2%）
Amplitude是一家美国企业，专注于研发数字分析软件，能够帮助企业梳理用户行为数据、优化产品决策与数字化运营体验。该公司于2021年9月28日在纳斯达克交易所挂牌上市，股票代码为AMPL。
Vericel Corp是一家美国上市生物制药企业，前身为1989年在密歇根州安娜堡成立的Aastrom Bio，2014年10月正式更为现名，专注于生物制药相关领域的研发与商业化运营。
AMPL vs VCEL — 直观对比
营收规模更大
VCEL
是对方的1.0倍
$91.4M
营收增速更快
VCEL
高出6.3%
17.0%
净利率更高
VCEL
高出44.3%
-19.3%
自由现金流更多
VCEL
多$177.0K
$12.7M
两年增速更快
VCEL
近两年复合增速
12.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $91.4M | $92.9M |
| 净利润 | $-17.7M | $23.2M |
| 毛利率 | 74.6% | 78.7% |
| 营业利润率 | -18.3% | 24.1% |
| 净利率 | -19.3% | 25.0% |
| 营收同比 | 17.0% | 23.3% |
| 净利润同比 | 45.8% | 17.3% |
| 每股收益（稀释后） | $-0.13 | $0.46 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPLVCEL
| Q4 25 | $91.4M | $92.9M | ||
| Q3 25 | $88.6M | $67.5M | ||
| Q2 25 | $83.3M | $63.2M | ||
| Q1 25 | $80.0M | $52.6M | ||
| Q4 24 | $78.1M | $75.4M | ||
| Q3 24 | $75.2M | $57.9M | ||
| Q2 24 | $73.3M | $52.7M | ||
| Q1 24 | $72.6M | $51.3M |
净利润AMPLVCEL
| Q4 25 | $-17.7M | $23.2M | ||
| Q3 25 | $-24.0M | $5.1M | ||
| Q2 25 | $-24.7M | $-553.0K | ||
| Q1 25 | $-22.2M | $-11.2M | ||
| Q4 24 | $-32.6M | $19.8M | ||
| Q3 24 | $-16.9M | $-901.0K | ||
| Q2 24 | $-23.4M | $-4.7M | ||
| Q1 24 | $-21.5M | $-3.9M |
毛利率AMPLVCEL
| Q4 25 | 74.6% | 78.7% | ||
| Q3 25 | 73.9% | 73.5% | ||
| Q2 25 | 72.6% | 73.7% | ||
| Q1 25 | 74.7% | 69.0% | ||
| Q4 24 | 74.7% | 77.6% | ||
| Q3 24 | 75.1% | 71.9% | ||
| Q2 24 | 73.4% | 69.5% | ||
| Q1 24 | 74.0% | 68.9% |
营业利润率AMPLVCEL
| Q4 25 | -18.3% | 24.1% | ||
| Q3 25 | -26.0% | 5.1% | ||
| Q2 25 | -29.0% | -3.2% | ||
| Q1 25 | -26.8% | -24.3% | ||
| Q4 24 | -41.2% | 24.5% | ||
| Q3 24 | -21.4% | -4.3% | ||
| Q2 24 | -31.7% | -11.5% | ||
| Q1 24 | -29.0% | -10.7% |
净利率AMPLVCEL
| Q4 25 | -19.3% | 25.0% | ||
| Q3 25 | -27.1% | 7.5% | ||
| Q2 25 | -29.6% | -0.9% | ||
| Q1 25 | -27.8% | -21.4% | ||
| Q4 24 | -41.7% | 26.3% | ||
| Q3 24 | -22.4% | -1.6% | ||
| Q2 24 | -31.9% | -8.9% | ||
| Q1 24 | -29.5% | -7.5% |
每股收益（稀释后）AMPLVCEL
| Q4 25 | $-0.13 | $0.46 | ||
| Q3 25 | $-0.18 | $0.10 | ||
| Q2 25 | $-0.19 | $-0.01 | ||
| Q1 25 | $-0.17 | $-0.23 | ||
| Q4 24 | $-0.25 | $0.40 | ||
| Q3 24 | $-0.14 | $-0.02 | ||
| Q2 24 | $-0.19 | $-0.10 | ||
| Q1 24 | $-0.18 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $192.0M | $137.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $245.3M | $354.6M |
| 总资产 | $420.7M | $488.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMPLVCEL
| Q4 25 | $192.0M | $137.5M | ||
| Q3 25 | $189.2M | $135.4M | ||
| Q2 25 | $208.1M | $116.9M | ||
| Q1 25 | $209.0M | $112.9M | ||
| Q4 24 | $241.1M | $116.2M | ||
| Q3 24 | $319.9M | $101.7M | ||
| Q2 24 | $318.3M | $102.5M | ||
| Q1 24 | $316.1M | $110.6M |
股东权益AMPLVCEL
| Q4 25 | $245.3M | $354.6M | ||
| Q3 25 | $262.2M | $321.9M | ||
| Q2 25 | $279.5M | $306.8M | ||
| Q1 25 | $289.5M | $295.5M | ||
| Q4 24 | $296.6M | $292.0M | ||
| Q3 24 | $290.0M | $257.5M | ||
| Q2 24 | $287.3M | $243.0M | ||
| Q1 24 | $289.2M | $233.9M |
总资产AMPLVCEL
| Q4 25 | $420.7M | $488.0M | ||
| Q3 25 | $438.1M | $453.3M | ||
| Q2 25 | $456.6M | $435.6M | ||
| Q1 25 | $445.8M | $424.6M | ||
| Q4 24 | $445.9M | $432.7M | ||
| Q3 24 | $445.6M | $390.4M | ||
| Q2 24 | $445.4M | $376.8M | ||
| Q1 24 | $437.9M | $356.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $12.8M | $15.0M |
| 自由现金流经营现金流 - 资本支出 | $12.7M | $12.8M |
| 自由现金流率自由现金流/营收 | 13.8% | 13.8% |
| 资本支出强度资本支出/营收 | 0.2% | 2.4% |
| 现金转化率经营现金流/净利润 | — | 0.65× |
| 过去12个月自由现金流最近4个季度 | $28.2M | $24.7M |
8季度趋势，按日历期对齐
经营现金流AMPLVCEL
| Q4 25 | $12.8M | $15.0M | ||
| Q3 25 | $5.0M | $22.1M | ||
| Q2 25 | $20.1M | $8.2M | ||
| Q1 25 | $-8.0M | $6.6M | ||
| Q4 24 | $3.2M | $22.2M | ||
| Q3 24 | $6.2M | $10.2M | ||
| Q2 24 | $9.2M | $18.5M | ||
| Q1 24 | $-48.0K | $7.2M |
自由现金流AMPLVCEL
| Q4 25 | $12.7M | $12.8M | ||
| Q3 25 | $4.5M | $19.5M | ||
| Q2 25 | $19.5M | $81.0K | ||
| Q1 25 | $-8.5M | $-7.6M | ||
| Q4 24 | $2.4M | $8.5M | ||
| Q3 24 | $6.2M | $-9.2M | ||
| Q2 24 | $8.6M | $1.8M | ||
| Q1 24 | $-405.0K | $-6.8M |
自由现金流率AMPLVCEL
| Q4 25 | 13.8% | 13.8% | ||
| Q3 25 | 5.1% | 28.8% | ||
| Q2 25 | 23.4% | 0.1% | ||
| Q1 25 | -10.6% | -14.5% | ||
| Q4 24 | 3.1% | 11.2% | ||
| Q3 24 | 8.2% | -15.9% | ||
| Q2 24 | 11.8% | 3.4% | ||
| Q1 24 | -0.6% | -13.3% |
资本支出强度AMPLVCEL
| Q4 25 | 0.2% | 2.4% | ||
| Q3 25 | 0.5% | 3.9% | ||
| Q2 25 | 0.6% | 12.9% | ||
| Q1 25 | 0.5% | 27.0% | ||
| Q4 24 | 1.0% | 18.3% | ||
| Q3 24 | 0.0% | 33.5% | ||
| Q2 24 | 0.8% | 31.8% | ||
| Q1 24 | 0.5% | 27.3% |
现金转化率AMPLVCEL
| Q4 25 | — | 0.65× | ||
| Q3 25 | — | 4.35× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.12× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPL
| US | $55.8M | 61% |
| International | $35.7M | 39% |
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
